T. Rowe Price Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-81,773
| Closed | -$278K | – | 2623 |
|
|
2018
Q3 | $278K | Buy |
81,773
+28,781
| +54% | +$104K | ﹤0.01% | 2380 |
|
|
2018
Q2 | $199K | Buy |
52,992
+97
| +0.2% | +$472 | ﹤0.01% | 2463 |
|
|
2018
Q1 | $216K | Buy |
52,895
+175
| +0.3% | +$815 | ﹤0.01% | 2389 |
|
|
2017
Q4 | $245K | Buy |
52,720
+26,000
| +97% | +$143K | ﹤0.01% | 2348 |
|
|
2017
Q3 | $190K | Sell |
26,720
-11,800
| -31% | -$84.8K | ﹤0.01% | 2424 |
|
|
2017
Q2 | $278K | Sell |
38,520
-5,726
| -13% | -$35.8K | ﹤0.01% | 2273 |
|
|
2017
Q1 | $273K | Hold |
44,246
| – | – | ﹤0.01% | 2294 |
|
|
2016
Q4 | $259K | Sell |
44,246
-12,700
| -22% | -$69.4K | ﹤0.01% | 2299 |
|
|
2016
Q3 | $302K | Buy |
56,946
+21,100
| +59% | +$114K | ﹤0.01% | 2212 |
|
|
2016
Q2 | $237K | Sell |
35,846
-54
| -0.2% | -$302 | ﹤0.01% | 2263 |
|
|
2016
Q1 | $168K | Buy |
35,900
+17,400
| +94% | +$69.4K | ﹤0.01% | 2325 |
|
|
2015
Q4 | $93K | Sell |
18,500
-11,300
| -38% | -$53.7K | ﹤0.01% | 2433 |
|
|
2015
Q3 | $105K | Hold |
29,800
| – | – | ﹤0.01% | 2401 |
|
|
2015
Q2 | $297K | Buy |
29,800
+6,100
| +26% | +$65.4K | ﹤0.01% | 2202 |
|
|
2015
Q1 | $302K | Sell |
23,700
-1,080
| -4% | -$13.9K | ﹤0.01% | 2187 |
|
|
2014
Q4 | $351K | Sell |
24,780
-3,620
| -13% | -$56.1K | ﹤0.01% | 2115 |
|
|
2014
Q3 | $391K | Hold |
28,400
| – | – | ﹤0.01% | 2045 |
|
|
2014
Q2 | $437K | Hold |
28,400
| – | – | ﹤0.01% | 2007 |
|
|
2014
Q1 | $484K | Hold |
28,400
| – | – | ﹤0.01% | 1929 |
|
|
2013
Q4 | $368K | Sell |
28,400
-14,400
| -34% | -$172K | ﹤0.01% | 2044 |
|
|
2013
Q3 | $432K | Buy |
42,800
+24,600
| +135% | +$219K | ﹤0.01% | 1946 |
|
|
2013
Q2 | $136K | Buy |
+18,200
| New | +$142K | ﹤0.01% | 2282 |
|
T. Rowe Price Associates's KERX Position: Q4 2018 in Review
T. Rowe Price Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 81,773 shares — an estimated $278K sold.
T. Rowe Price Associates first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $484K in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- T. Rowe Price Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- T. Rowe Price Associates sold 81,773 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $278K.
- T. Rowe Price Associates first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- T. Rowe Price Associates's Keryx Biopharmaceuticals Inc position peaked at $484K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.